Sign in to view content

APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies

Michael J Allingham, MD, PhD

Video
Published 2021

Related

Episode 4: 3-year Results of the TREX-AMD Trial with Dr. Charles Wykoff
Keyvan Koushan, MD, FRCSC
Member Podcasts
2017
PULSAR Extension: Clinical Improvements Sustained Over 156 Weeks With Aflibercept 8 mg in Patients With Neovascular Age-Related Macular Degeneration
David T.W. Wong, MD, FRCS(C), FASRS
Updates from the Field
2025
New Treatment Paradigm for Infectious Endophthalmitis: Results from the Mexican Endophthalmitis Study Group Protocol 1 and 3
Raul Velez-Montoya, MD
Updates from the Field
2024

Category: Diabetic Retinopathy

See more